



Solventum[™] V.A.C.[®] Therapy

Collection of case studies

Introduction


This booklet includes case studies across several wound types. As with any case study, the results and outcomes should not be interpreted as a guarantee or warranty of similar results. Individual results may vary depending on the patient's condition and circumstances.

Table of contents

- 5 Solventum™ V.A.C.® Therapy indications
- 6 Key publications
- 7 Case study 1: Mestastatic melanoma of the right lower extremity
- 8–9 Case study 2: Management of a chronic diabetic foot ulcer with V.A.C.® Therapy with Solventum™ V.A.C.® Granufoam™ Silver Dressing
- 10–11 Case study 3: V.A.C.® Therapy with Solventum™ V.A.C.® Granufoam™ Silver Dressing in management of wound created by abscess of the right groin
- 12 Case study 4: Management of a lower extremity trauma wound using V.A.C.® Therapy with V.A.C.® Granufoam™ Dressing
- 13–14 Case study 5: Management of a lower extremity DFU with cellulitis with infected submetatarsal 5 ulceration
- 15–16 V.A.C.® Therapy ordering information
- 16–17 References


Mechanism of action

The integrated V.A.C.® Therapy System has a unique mechanism of action whereby the delivery of negative pressure using the V.A.C.® Granufoam™ Dressing not only maintains a moist wound environment that promotes healing, but also stimulates physiologic responses important to wound healing. These responses are observed at the tissue and cellular levels. Macrostrain approximates the tissue edges, minimizing the tissue defect size.¹⁻³ Microstrain stimulates increased cellular proliferation, leading to angiogenesis and granulation tissue formation.⁴⁻⁶ These effects, as predicated by the adequate delivery of negative pressure to the wound site, are translated into clinical outcomes such as improved tissue perfusion,⁷ reduced tissue edema⁸ and increased granulation tissue formation.⁹ The scientific foundation for V.A.C.® Therapy forms the basis for the improved patient outcomes observed in the published clinical literature and supports its use for temporizing wounds and protecting them from external contamination during long-term care.



Solventum™ V.A.C.® Therapy indications

These Solventum NPWT products are indicated for the following wound types:



Key publications demonstrating the efficacy of Solventum™ V.A.C.® Therapy NPWT

The body of literature provides evidence to V.A.C.® Therapy's effectiveness in diabetic foot wounds, chronic wounds such as pressure ulcers and lower extremity ulcers, and a wide variety of acute wounds (Table 1 below).

Wound type	Key publications — Acute wounds
Surgical wounds	Zannis et al. 2009 (PCT) ¹⁰ Siegel et al. 2007 (CRS) ¹¹ Biter et al. 2014 (RCT) ¹² Zenke et al. 2014 (PCT) ¹³ Seidel et al. 2020 (RCT) ¹⁴
General trauma	Machen et al. 2007 (CSE) ¹⁵ Labler et al. 2007 (CST) ¹⁶ Raj et al. 2016 (PCT) ¹⁷ Maurya et al. 2017 (PC) ¹⁸ Burt et al. 2020 (CRS) ¹⁹
Grafts	Blume et al. 2010 (RS) ²⁰ Ho et al. 2013 (PCT) ²¹ Eisenhardt et al. 2011(RCT) ²² Joo et al. 2020 (RCT) ²³ Vather et al. 2018 (RCT) ²⁴ Halama et al. 2019 (RCT) ²⁵
Diabetic foot amputations	Lavery et al. 2008 (RS) ²⁶ Armstrong et al. 2005 (RCT) ²⁷ Dalla Paola et al. 2010 (RCT) ²⁸ Eginton et al. 2003 (RCT) ²⁹ De Caridi et al. 2016 (PCT) ³⁰ Sukur et al. 2018 (CRS) ³¹
Wound type	Key publications — Chronic wounds
Pressure	Warner et al. 2003 (RCT) ³² Ford et al. 2002 (RCT) ³³ Joseph et al. 2000 (RCT) ³⁴ Wild et al. 2008 (RCT) ³⁵ Fulco et al. 2015 (RCT) ³⁶ Wagstaff et al. 2014 (RCT) ³⁷
Diabetic foot	Suissa et al. 2011 (Meta Analysis) ³⁸ Blume et al. 2008 (RCT) ³⁹ Cole et al. 2016 (PCT) ⁴⁰ Skrinjar et al. 2016 (RCT) ⁴¹ Maranna et al. 2021 (RCT) ⁴²
Venous stasis ulcer	Vuerstaek et al. 2006 (RCT) ⁴³ Dini et al. 2010 (RCT) ⁴⁴ Egemen et al. 2012 (PCT) ⁴⁵

CRS: Comparative Retrospective Study; CSE: Case Series; CST: Case Study; RCT: Randomized Controlled Trial; RS: Retrospective Study

Case study 1

A case of metastatic melanoma of the right lower extremity

Sutter Pacific Medical Foundation at California Pacific Medical Center, San Francisco, CA

Patient

A 68-year-old retired male police officer developed wound breakdown (due to infection) following a right radical ilioinguinal lymph node resection for melanoma. His previous medical history included hypertension, hypothyroidism, hypercalcemia, degenerative disc disease, prediabetes, basal cell carcinoma, and chronic pain.

Diagnosis

Patient developed postoperative right groin wound infection. At presentation, the wound was 20 cm x 10 cm x 6 cm and copiously draining (**Figure 1**).

Course of treatment

Systemic antibiotics were administered, and the wound was surgically debrided followed by application of Solventum™ V.A.C.® Therapy using a negative pressure of -125 mmHg in the clinic. (**Figure 2**). V.A.C.® Therapy was continued for five weeks with dressing changes occurring three times per week. Excellent granulation tissue formation was noted after one week with V.A.C.® Therapy (**Figure 3**). All treatments were delivered in the clinic setting without the need for any intra-operative procedures.

Discharge and follow up

After five weeks, V.A.C.® Therapy was discontinued, and the wound was sutured (**Figure 4**). After suturing the wound, a local wound care clinic applied standard dressings, which were changed according to manufacturer's instructions until complete wound healing three months after discontinuing V.A.C.® Therapy (**Figure 5**).



Figure 1. Wound at presentation.



Figure 2. Initial application of V.A.C.® Therapy after surgical debridement (Day 1).



Figure 3. Wound after 1 week of V.A.C.® Therapy.



Figure 4. Primary wound closure after 5 weeks of V.A.C.® Therapy.



Figure 5. Complete wound closure at long-term follow-up (3 months after discontinuing V.A.C.® Therapy).

Case study 2

Case Study 2: Management of a chronic diabetic foot ulcer with Solventum™ V.A.C.® Therapy with Solventum™ V.A.C.® Granufoam™ Silver Dressing

Brent Bernstein, DPM, Diamond Podiatry; Bethlehem, PA

Patient

A 64-year-old female patient presented to the hospital with a stage 3 diabetic ulcer measuring 2.5 x 2.5 x 0.3 cm³ (**Figure 1**) that had been present in the right foot for 4 months. Her comorbidities included type 2 diabetes, morbid obesity, hypertension, Charcot neuroarthropathy of the left foot, bilateral peripheral neuropathy of the lower extremities, and a recent history of gallbladder tumor with chemotherapy and radiation less than a year prior.

Diagnosis

The patient was examined and diagnosed with a medial ulceration of the right first metatarsophalangeal joint with osteomyelitis of the exposed head of the first metatarsal and base of the proximal phalanx. Previous treatment included daily application of gentian violet with a dry sterile dressing. No antibiotic therapy or bone biopsy had been performed. Bacterial cultures were taken, and the wound was positive for Beta Hemolytic Streptococcus Group G, Enterococcus species, and methicillin-resistant Staphylococcus aureus. Organism-specific antibiotics were administered intravenously. Two days after presenting to the hospital, the patient underwent surgical debridement via resection of the first metatarsal head and base of the proximal phalanx, with diastasis permitted with a mini-external fixator (**Figure 2**).

Course of treatment

Post-debridement wound measurements were 5.0 x 3.0 x 1.9 cm.³ Twenty-four hours after surgery, V.A.C.® Therapy with V.A.C.® Granufoam Silver Dressing was applied at -125 mmHg (**Figure 3**). Dressings were changed every 3 days, at which point the wound was reassessed (**Figure 4**). The goal of therapy was wound bed preparation, granulation tissue formation, and removal of infectious materials. During therapy, the patient was required to be strictly non-weightbearing in a wheelchair.

Discharge and follow up

After 41 days, the goals of therapy were achieved, and the external fixator was removed (**Figure 5**). A split-thickness skin graft (STSG) was harvested from the ipsilateral calf. The STSG was applied following a 2:1 mesh ratio to the wound surface (**Figure 6**), then covered with a non-adherent dressing. V.A.C.® Therapy with V.A.C.® Granufoam Silver Dressing was resumed at -125 mmHg to bolster the STSG (**Figure 7**). After 5 days, 100% STSG take was evident, and V.A.C.® Therapy was discontinued. Upon follow-up 3.5 months after STSG, the wound remained healed (**Figure 8**). -125 mmHg to bolster the STSG (**Figure 7**). After 5 days, 100% STSG take was evident, and V.A.C.® Therapy was discontinued. Upon follow-up 3.5 months after STSG, the wound remained healed (**Figure 8**).



Figure 1. Diabetic ulcer at presentation.



Figure 2. Wound appearance after debridement and external fixation.



Figure 3. Application of Solventum™ V.A.C.® Therapy with Solventum™ V.A.C.® Granufoam™ Silver Dressing.



Figure 4. Wound appearance after 19 days of V.A.C.® Therapy with V.A.C.® Granufoam Silver Dressing.



Figure 5. Wound appearance after 41 days of V.A.C.® Therapy with V.A.C.® Granufoam Silver Dressing.



Figure 6. Application of meshed STSG.



Figure 7. Application of V.A.C.® Therapy with V.A.C.® Granufoam Silver Dressing to bolster the STSG.



Figure 8. Wound closed at 3.5-month follow-up visit.

Case study 3

Solventum™ V.A.C.® Therapy with Solventum™ V.A.C.® Granufoam™ Dressing in management of wound created by abscess of the right groin

Michael Robinowitz, MD, Piedmont Atlanta Hospital, Atlanta, GA

Patient

A 43-year-old male presented to the hospital with pain, erythema, and swelling in his right groin that had persisted for 1 week. Initial care included antibiotics, aseptic skin cleanser, warm compresses, and incision and drainage of the abscess. Seven days later, the patient presented to the emergency room with a fever and increased right groin erythema, edema, and tenderness. The patient was admitted with a soft tissue infection, abscess, and sepsis. Upon examination, the patient was found to have a small punctate opening in the right lateral suprapubic area was observed, with marked erythema down to the inguinal ligaments. Necrotic skin and marked fluctuance were present. A computed tomography (CT) scan of the pelvis indicated an elongated skin defect or wound in the upper anterior right thigh with extensive subcutaneous inflammatory changes, with nonoccluded fluid densities, edema, and extensive gas bubbles extending from 20 cm below the hip joint to the right inguinal region and the base of the scrotum. Necrotizing fasciitis could not be ruled out.

Diagnosis

The patient was taken to the operating room for exploration and surgical debridement of necrotic skin, subcutaneous tissue, and muscle tissue in the right thigh (**Figure 1**). The postoperative diagnosis suspected necrotizing fasciitis of the right thigh up to, but not involving, the scrotum. The wound was irrigated via pulsed lavage and packed with oxychlorosene-soaked gauze. Hyperbaric oxygen (HBO) therapy was started. Additional surgical debridement and irrigation with pulsed lavage were performed due to the progression of necrotizing infection into the posterior and distal thigh (**Figure 2**). Clindamycin was added to the intravenous antibiotics. HBO treatments were continued, and the infectious disease service was consulted. Systemic antibiotics were continued, and a peripherally inserted central catheter (PICC) line was ordered. Dressings were changed daily with wet-to-moist gauze soaked with oxychlorosene solution. The PICC line was placed, and antibiotics were continued.

Course of treatment

V.A.C.® Therapy at -125 mmHg was initiated 7 days following presentation to the emergency room. At the time of application, the wound measured 29 x 24 x 2 cm³ with a 2.5 cm tract and 4.2 cm undermining. The wound contained <10% yellow slough in the wound bed. Both V.A.C.® Granufoam and Solventum™ V.A.C.® White Foam Dressings were used. The patient noted only procedural pain during dressing changes. Wound care staff changed the dressings 3 times a week. Nine days after presentation, the patient was discharged with a PICC line, intravenous antibiotic therapy, and V.A.C.® Therapy with home healthcare for dressing changes 3 times a week. After 21 days, the wound measurements were 25.5 x 20 x 0.3 cm³, and bright red granulation tissue covered 100% of the wound bed (**Figure 3**). Moderate serosanguineous drainage was also observed. V.A.C.® Therapy was discontinued, and the plan of care was changed to a silver alginate dressing with a gauze dressing bolster and self-adhesive wrap to be changed 3 times per week. At each follow-up visit, the wound size decreased, and there were no further signs of infection (**Figure 4**).

Discharge and follow up

The patient regained full range of motion, mobility, and gait without skilled therapy intervention. At the last clinic visit, the wound measured 11.7 x 1.4 x 0.1 cm³ (**Figure 5**). The patient was discharged 3 months following the last clinic visit (**Figure 6**).



Figure 1. Right thigh wound following surgical debridement and wet-to-moist oxychlorosene-soaked gauze (postoperative Day 1).



Figure 2. Right thigh wound following 2 hyperbaric oxygen treatments and minimal sharp debridement of loose nonviable tissue during wet-to-moist oxychlorosene gauze dressing change (postoperative Day 2).



Figure 3. Right thigh wound following 21 days of Solventum™ V.A.C.® Therapy (postoperative Day 26).



Figure 4. Right thigh following use of silver alginate dressing (postoperative Day 42).



Figure 5. Wound healing by contraction with 100% granulation tissue (postoperative Day 105).



Figure 6. Right thigh wound completely healed 8 months following presentation to the emergency room.

Case study 4

Management of a lower extremity trauma wound using Solventum™ V.A.C.® Therapy with Solventum™ V.A.C.® Granufoam™ Dressing

D. Heath Stacey, MD, Northwest Arkansas Center for Plastic Surgery; Fayetteville, AR

Patient

A 46-year-old male with no significant past medical history presented to the hospital with a significant multi-level lower extremity trauma injury. After receiving care under an orthopedic surgeon, he was referred to a plastic surgeon for soft tissue closure. The patient's external fixator had been removed, and an intramedullary rod had been placed in his tibia.

Diagnosis

The wound bed exhibited granulation tissue and eschar overlying the tibia on the middle third of the leg (**Figure 1**). After debridement, the bone was exposed (**Figure 2**).

Course of treatment

V.A.C.® Therapy was applied at -125 mmHg using V.A.C.® Granufoam Dressing. After 1 week, the wound showed signs of healing (**Figure 3**), but exposed fragments of tibia remained distally. A debridement was performed and V.A.C.® Therapy with V.A.C.® Granufoam Dressing was resumed. After the second week, the wound was ready for closure. Split thickness skin grafting was used to cover the granulation tissue over muscles, and a hemi-soleus muscle flap was used to cover the tibia (**Figure 4**).

Discharge and follow up

Upon follow-up, the wound was closed (**Figure 5**) and the patient was ambulatory.



Figure 1. Left leg upon presentation.



Figure 2. Wound after initial debridement.



Figure 3. Wound after 1 week of V.A.C.® Therapy with V.A.C.® Granufoam Dressing.



Figure 4. Intraoperative photo of wound closure with split thickness skin graft and a hemi-soleus muscle flap.



Figure 5. Wound remained closed upon follow-up.

Case study 5

Management of a lower extremity DFU with cellulitis with infected submetatarsal 5 ulceration

Brent Bernstein, DPM, Diamond Podiatry; Bethlehem, PA

Patient

A 64-year-old Hispanic male (Patient 3) with a history of poorly controlled type II diabetes, hypertension, peripheral vascular disease, peripheral neuropathy, was admitted for right lower extremity cellulitis with infected submetatarsal 5 ulceration with suspected osteomyelitis. The ulcer had developed 4 weeks prior and it had worsened over time. He then sought treatment in Puerto Rico and was instructed on local wound care and a prescription for amoxicillin clavulanate. Despite this, he developed a fever, chills, pain, swelling, and loss of right leg function 3 days prior to returning to the United States for more definitive treatment.

Diagnosis

Examination revealed right submetatarsal 5 ulceration, probing to the 5th metatarsal head plantarly. The ulceration measured 4.0 x 4.0 cm² with a necrotic wound bed and foul odor. Dishwater pus was draining from the wound. There was erythema around the ulcer, extending proximally to the right knee with significant swelling. There was undermining and tunneling from the ulcer to the dorsal foot with blistering of the dorsal foot. A palpable dorsalis pedis and posterior pulse was present. Cutaneous sensation was absent.

Course of treatment

An immediate bedside incision and drainage was performed to decompress the lesion on the first day of admission with planned radical operative debridement for the following day. A diagnosis of necrotizing fasciitis and contiguous focus osteomyelitis was made.

Hospital course

Initially, vancomycin and cefepime were administered and switched to penicillin on the 5th day upon culture result. Bedside incision and drainage was performed on the first day of hospitalization and he was taken to the operative theatre the following day for partial 5th ray resection and radical wound debridement. Intra-operative findings were consistent with strep infection including liquefaction of the subcutaneous tissue and thrombosis of vessels. The dorsal ankle and foot were degloved of infected tissue followed by pulsed lavage irrigation. Solventum™ V.A.C.® Granufoam™ Dressing was applied to the surgical wound. A 2nd debridement and irrigation was performed on the 3rd day with continued Solventum™ V.A.C.® Therapy. A 3rd wound debridement and a split thickness skin graft was performed 4 days later with continuous V.A.C.® Therapy at -75 mmHg used to bolster the skin graft. V.A.C.® Therapy was discontinued on the 10th day of hospitalization and local skin graft care was initiated. The patient was discharged to home on the 12th day and antibiotic therapy with penicillin was continued for 5 days.

Osteomyelitis was diagnosed from X-ray findings and confirmed with intra-operative bone biopsy.

Discharge and follow up

All outpatient care was supervised by the initial surgeon. Approximately 35% loss of the initial split thickness skin graft was noted at the first outpatient follow-up 3 days after discharge from the hospital. Residual wounds measured 13.5 x 10.0 x 0.5 cm³. Exposed bone over the cuboid as well as exposed peroneus brevis tendon were noted. Local wound care was performed with excision debridement and collagenase dressings weekly.

V.A.C.® Therapy with Solventum™ V.A.C.® Granufoam™ Silver Dressing was initiated 1 month after discharge from the hospital, with wound measurement of 12.5 x 8.0 x 0.5 cm³. A biopsy of exposed bone removed with rongeur debridement prior to initial V.A.C.® Granufoam Silver Dressing was positive for osteomyelitis. The patient received oral cephalexin and V.A.C.® Therapy with V.A.C.® Granufoam Silver Dressing was continued. A bone debridement and biopsy revealed pseudomonas aeruginosa, and antibiotics were changed to oral ciprofloxacin.

After 3 weeks of Solventum™ V.A.C.® Therapy with Solventum™ V.A.C.® Granufoam™ Silver Dressing, the size of the wound decreased to 8.0 x 7.5 x 0.2 cm³. Wound tissue cultures revealed pseudomonas aeruginosa, enterococcus, and enterobacter cloacae. Weekly soft tissue wound debridements were continued with interval V.A.C.® Granufoam Silver Dressing changes occurring with home care nursing, with a temporary hold on V.A.C.® Therapy in the 5th week due to lower leg pain and a venous duplex revealing a ruptured Baker's cyst. Oral cephalexin was started. A wound tissue culture showed pseudomonas aeruginosa and enterobacter cloacae and the prescription was changed to ciprofloxin. V.A.C.® Therapy with V.A.C.® Granufoam Silver Dressing was resumed after 1 week, being changed 3 times per week. A 3rd bone debridement occurred 2 weeks later.

After a total of 8 weeks of V.A.C.® Therapy with V.A.C.® Granufoam Silver Dressing, the wound was noted to have adequate granulation coverage of the bone and peroneal tendon. A cultured skin graft and a meshed bi-layered cultured graft was placed on the residual wound on and V.A.C.® Therapy was discontinued. A meshed silicone dressing was placed over the graft and left in place. One week later, the graft was evaluated and noted to be incorporating well with active contracture of the wound. At last follow-up 2 weeks post graft application, continued contracture was noted with a loose fragment of bone noted and resected from the wound.



Figure 1. Patient 3 Initial Presentation Post Debridement



Figure 2. Patient 3 Initial Split Thickness Skin Graft



Figure 3. Patient 3 Partial SPTSG failure prior to V.A.C.® Granufoam Silver Dressing



Figure 4. Patient 3 Post- V.A.C.® Granufoam Silver Dressing



Figure 5. Patient 3 Cultured allograft application



Figure 6. Patient 3 wound closure

Solventum™ V.A.C.® Therapy ordering information

Solventum™ V.A.C.® Dressings	Dimensions	Part number/ Dressings per case	
Solventum™ V.A.C.® Simplace™ Ex Dressing Kit* – Small	(7.7 x 11.2 x 1.75 cm)	M8275046/5	
Solventum™ V.A.C.® Simplace™ Ex Dressing Kit* – Medium	(14.7 x 17.4 x 1.75 cm)	M8275045/5	
Solventum™ V.A.C.® Simplace™ Dressing Kit w/3M™ Tegaderm™ Tape* – Small	(7.7 x 11.2 x 1.75 cm)	M8275041/10 M8275041/5	
Solventum™ V.A.C.® Simplace™ Dressing Kit w/3M™ Tegaderm™ Tape* – Medium	(14.7 x 17.4 x 1.75 cm)	M8275040/10 M8275040/5	
Solventum™ V.A.C.® Granufoam™ Bridge Dressing Kit*	(6 x 17 x 1.9 cm)	M8275042/10 M8275042/5	
Solventum™ V.A.C.® Granufoam™ Bridge XG Dressing Kit*	(6 x 17 x 1.9 cm)	M8275044/5	
Solventum™ V.A.C.® Granufoam™ Dressing Kit* – Small	(10 x 7.5 x 3.2 cm)	M8275051/10 M8275051/5	
Solventum™ V.A.C.® Granufoam™ Dressing Kit* – Medium	(18 x 12.5 x 3.2 cm)	M8275052/10 M8275052/5	
Solventum™ V.A.C.® Granufoam™ Dressing Kit* - Large	(26 x 15 x 3.2 cm)	M8275053/10 M8275053/5	
Solventum™ V.A.C.® Granufoam™ Dressing Kit* – X-Large	(60 x 30 x 1.5 cm)	M8275065/5	
Solventum™ V.A.C.® Granufoam™ Silver Dressing Kit* – Small	(10 x 7.5 x 3.2 cm)	M8275098/10 M8275098/5	
Solventum™ V.A.C.® Granufoam™ Silver Dressing Kit* – Medium	(18 x 12.5 x 3.2 cm)	M8275096/10 M8275096/5	
Solventum™ V.A.C.® Granufoam™ Silver Dressing Kit* – Large	(26 x 15 x 3.2 cm)	M8275099/10 M8275099/5	
Solventum™ V.A.C.® White Foam Dressing Kit* – Small	(10 x 7.5 x 1 cm)	M8275068/10 M8275068/5	
Solventum™ V.A.C.® White Foam Dressing Kit* – Large	(10 x 15 x 1 cm)	M8275067/10 M8275067/5	
Solventum™ V.A.C.® White Foam Dressing – Small (foam only)	(10 x 7.5 x 1 cm)	M6275033/10	
Solventum™ V.A.C.® White Foam Dressing – Large (foam only)	(10 x 15 x 1 cm)	M6275034/10	

*Kit includes foam dressing, drape(s), 1 disposable ruler, 1 Solventum™ SensaT.R.A.C.™ Pad with connector. Specifications subject to change at any time without notice.

Solventum™ V.A.C.® Therapy ordering information

V.A.C.® Therapy System accessories	Part number/Dressings per case	
Solventum™ SensaT.R.A.C.™ Pad Only	M8275057/10	
Solventum™ V.A.C.® Drape	M6275009/10	
Solventum™ V.A.C.® Y-Connector	M6275066/10 M6275066/5	
Solventum™ V.A.C.® Tubing Cap	M6275069/10 M6275069/5	

References

1. Morykwas MJ, Simpson J, Pungler K, Argenta A, Kremers L, Argenta J. Vacuum-assisted closure: state of basic research and physiologic foundation. *Plast Reconstr Surg* 2006;117:121S-126S.
2. Baharestani M, de Leon J, Mendez-Eastman S et al. Consensus Statement: A practical guide for managing pressure ulcers with negative pressure wound therapy utilizing vacuum-assisted closure- understanding the treatment algorithm. *Advances in Skin and Wound Care* 2008;21:1-20.
3. Baharestani MM, Driver VR, De Leon JM et al. Optimizing clinical and cost effectiveness with early intervention of V.A.C. therapy. *Ostomy Wound Manage* 2008;54:1-15.
4. Saxena V, Hwang CW, Huang S, Eichbaum Q, Ingber D, Orgill DP. Vacuum-assisted closure: microdeformations of wounds and cell proliferation. *Plast Reconstr Surg* 2004;114:1086-1096.
5. McNulty AK, Schmidt M, Feeley T, Villanueva P, Kieswetter K. Effects of negative pressure wound therapy on cellular energetics in fibroblasts grown in a provisional wound (fibrin) matrix. *Wound Repair Regen* 2009;17:192-199.
6. McNulty AK, Schmidt M, Feeley T, Kieswetter K. Effects of negative pressure wound therapy on fibroblast viability, chemotactic signaling, and proliferation in a provisional wound (fibrin) matrix. *Wound Repair Regen* 2007;15:838-846.
7. Wackenfors A, Sjogren J, Algotsson L, Gustafsson R, Ingemansson R, Malmsjo M. The effect of vacuum-assisted closure therapy on the pig femoral artery vasomotor responses. *Wound Repair Regen* 2004;12:244-251.
8. Kamolz LP, Andel H, Haslik W, Winter W, Meissl G, Frey M. Use of subatmospheric pressure therapy to prevent burn wound progression in human: first experiences. *Burns* 2004;30:253-258.
9. Morykwas MJ, Argenta LC, Shelton-Brown EI, McGuirt W. Vacuum-assisted closure: a new method for wound control and treatment: animal studies and basic foundation. *Ann Plast Surg* 1997;38:553-562.
10. Zannis J, Angobaldo J, Marks M et al. Comparison of fasciotomy wound closures using traditional dressing changes and the vacuum-assisted closure device. *Ann Plast Surg* 2009 April 1;62(4):407-9.
11. Siegel HJ, Long JL, Watson KM, Fiveash JB. Vacuum-assisted closure for radiation-associated wound complications. *J Surg Oncol* 2007 November 12;96(7):575-82.
12. Biter LU, Beck GM, Mannaerts GH, Stok MM, van der Ham AC, Grotenhuis BA. The use of negative-pressure wound therapy in pilonidal sinus disease: a randomized controlled trial comparing negative-pressure wound therapy versus standard open wound care after surgical excision. *Diseases of the Colon and Rectum*. 2014 Dec;57(12):1406-11.
13. Zenke Y, Inokuchi K, Okada H, Ooae K, Matsui K. Useful technique using negative pressure wound therapy on postoperative lower leg open wounds with compartment syndrome. *Injury Extra*. 2014 Sep;45(9):83-7.
14. Seidel D, Diedrich S, Herrle F, Thielemann H, Marusch F, Schirren R, Talaulicar R, Gehrig T, Lehwald-Tywuschik N, Glanemann M, Bunse J, Hüttemann M, Braumann C, Heizmann O, Miserez M, Krönert T, Gretschel S, Lefering R. Negative Pressure Wound Therapy vs Conventional Wound Treatment in Subcutaneous Abdominal Wound Healing Impairment: The SAWHI Randomized Clinical Trial. *JAMA Surg*. 2020 Jun 1;155(6):469-478
15. Machen MS. Management of traumatic war wounds using vacuum-assisted closure dressings in an austere environment. *Army Medical Department Journal* 2007 January 1;17-23.
16. Labler L, Trentz O. The use of vacuum assisted closure (VAC) in soft tissue injuries after high energy pelvic trauma. *Langenbecks Arch Surg* 2007 September 1;392(5):601-9.
17. Raj M, Gill SP, Sheopaltan SK, Singh P, Dinesh, Sigh J, Rastogi P, Mishra LN. Evaluation of Vacuum Assisted Closure Therapy for Soft Tissue Injury in Open Musculoskeletal Trauma. *J Clin Diagn Res*. 2016 Apr;10(4):RC05-8.

18. Maurya S, Srinath N, Bhandari PS. Negative pressure wound therapy in the management of mine blast injuries of lower limbs: Lessons learnt at a tertiary care center. *Med J Armed Forces India*. 2017 Oct;73(4):321-327. doi: 10.1016/j.mjafi.2016.06.002. Epub 2016 Jul 26. PMID: 29386704; PMCID: PMC5771719.
19. Burt KE, Badash I, Leland HA, Gould DJ, Rounds AD, Patel KM, Carey JN. The Efficacy of Negative Pressure Wound Therapy and Antibiotic Beads in Lower Extremity Salvage. *J Surg Res*. 2020 Mar;247:499-507. doi: 10.1016/j.jss.2019.09.055. Epub 2019 Nov 2. PMID: 31690532.
20. Blume PA, Key JJ, Thakor P, Thakor S, Sumpio B. Retrospective evaluation of clinical outcomes in subjects with split-thickness skin graft: comparing V.A.C.® Therapy and conventional therapy in foot and ankle reconstructive surgeries. *International Wound Journal* 2010 December 1;7(6):480-7.
21. Ho MW, Rogers SN, Brown JS, Bekiroglu F, Shaw RJ. Prospective evaluation of a negative pressure dressing system in the management of the fibula free flap donor site: a comparative analysis. *JAMA Otolaryngology - Head and Neck Surgery*. 2013 Oct;139(10):1048-53.
22. Eisenhardt SU, Schmidt Y, Thiele JR et al. Negative pressure wound therapy reduces the ischaemia/reperfusion-associated inflammatory response in free muscle flaps. *Journal of Plastic, Reconstructive and Aesthetic Surgery* 2012 May 1;65(5):640-9.
23. Joo et al 2020 (RCT) Joo HS, Lee SJ, Lee SY, Sung KY. The efficacy of negative pressure wound therapy for split thickness skin grafts for wounds on the trunk or neck: A randomized controlled trial. *Wounds*. 2020 Dec;32(12):334-38.
24. Vather R, Ker H, Rolfe G, Chen L, Hammodat H, Gale K, Martin R. Wound Outcomes in Negative Pressure Dressings (WOUND) study - A randomised trial in lower limb skin; cancer grafts. *J Plast Reconstr Aesthet Surg*. 2018 Jul;71(7):1100-1102. doi: 10.1016/j.bjps.2018.03.015. Epub 2018 Apr 9. PMID: 29793844.
25. Halama D, Dreilich R, Lethaus B, Bartella A, Pausch NC. Donor-site morbidity after harvesting of radial forearm free flaps-comparison of vacuum-assisted closure with conventional wound care: A randomized controlled trial. *J Craniomaxillofac Surg*. 2019 Dec;47(12):1980-1985. doi: 10.1016/j.jcms.2019.11.004. Epub 2019 Nov 25. PMID: 31810850.
26. Lavery LA, Murdoch DP, Baxter C, Brawner M. Negative pressure wound therapy reduces recurrent amputations. Presented at the Third Congress of the World Union of Wound Healing Societies, June 4-8, 2008, Toronto, Ontario. PF196. 6-4-2008. Ref Type: Abstract
27. Armstrong DG, Lavery LA, Diabetic Foot Study Consortium. Negative pressure wound therapy after partial diabetic foot amputation: a multicentre, randomised controlled trial. *Lancet* 2005 November 12;366(9498):1704-10.
28. Dalla Paola L, Carone A, Ricci S, Russo A, Ceccacci T, Ninkovic S. Use of vacuum assisted closure therapy in the treatment of diabetic foot wounds. *Journal of Diabetic Foot Complications* 2010 August 20;2(2):33-44.
29. Eginton MT, Brown KR, Seabrook GR, Towne JB, Cambria RA. A prospective randomized evaluation of negative-pressure wound dressings for diabetic foot wounds. *Ann Vasc Surg* 2003 November 1;17(6):645-9.
30. De Caridi G, Massara M, Greco M, Pipito N, Spinelli F, Grande R, Butrico L, de Franciscis S, Serra R. VAC therapy to promote wound healing after surgical revascularisation for critical lower limb ischaemia. *International Wound Journal*. 2016 Jun;13(3):336-42.
31. Sukur E, Akar A, Uyar AC, Cicekli O, Kochai A, Turker M, Topcu HN. Vacuum-assisted closure versus moist dressings in the treatment of diabetic wound ulcers after partial foot amputation: A retrospective analysis in 65 patients. *Journal of Orthopaedic Surgery*. 2018 Sep-Dec;26(3):2309499018799769.
32. Warner MB, Schwarzl F, Strub B, Zaech GA, Pierer G. Vacuum-assisted wound closure for cheaper and more comfortable healing of pressure sores: a prospective study. *Scand J Plast Reconstr Surg Hand Surg* 2003 January 1;37(1):28-33.
33. Ford CN, Reinhard ER, Yeh D et al. Interim analysis of a prospective, randomized trial of vacuum-assisted closure versus the healthpoint system in the management of pressure ulcers. *Ann Plast Surg* 2002 July 2;49(1):55-61.
34. Joseph E, Hamori CA, Bergman S, Roaf E, Swann NF, Anastasi GW. A prospective, randomized trial of vacuum-assisted closure versus standard therapy of chronic nonhealing wounds. *Wounds* 2000 May 1;12(3):60-7.
35. Wild T, Stremitzer S, Hoelzenbein T, Ludwig C, Ohrenberger G. Definition of efficiency in vacuum therapy-a randomized controlled trial comparing Redon drains with V.A.C.® Therapy. *International Wound Journal* 2008 December 1;5(5):641-7.
36. Fulco I, Erba P, Valeri RC, Vournakis J, Schaefer DJ. Poly-N-acetyl glucosamine nanofibers for negative-pressure wound therapies. *Wound Repair and Regeneration*. 2015 Mar-Apr;23(2):197-202.
37. Wagstaff MJ, Driver S, Coghlan P, Greenwood JE. A randomized, controlled trial of negative pressure wound therapy of pressure ulcers via a novel polyurethane foam. *Wound Repair and Regeneration*. 2014 Mar-Apr;22(2):205-11.
38. Suissa D, Danino A, Nikolis A. Negative-Pressure Therapy versus Standard Wound Care: A Meta-Analysis of Randomized Trials. *Plast Reconstr Surg* 2011 November 1;128(5):498e-503e.
39. Blume PA, Walters J, Payne W, Ayala J, Lantis J. Comparison of negative pressure wound therapy using vacuum-assisted closure with advanced moist wound therapy in the treatment of diabetic foot ulcers: a multicenter randomized controlled trial. *Diabetes Care* 2008 April 1;31(4):631-6.
40. Cole WE. Use of Multiple Adjunctive Negative Pressure Wound Therapy Modalities to Manage Diabetic Lower-Extremity Wounds. *Eplasty*. 2016 Dec 20;16:e34.
41. Skrinjar E, Duschek N, Bayer GS, Assadian O, Koulas S, Hirsch K, Basic J, Assadian A. Randomized controlled trial comparing the combination of a polymeric membrane dressing plus negative pressure wound therapy against negative pressure wound therapy alone: The WICVAC study. *Wound Repair and Regeneration*. 2016 Sep;24(5):928-935.
42. Maranna H, Lal P, Mishra A, Bains L, Sawant G, Bhatia R, Kumar P, Beg MY. Negative pressure wound therapy in grade 1 and 2 diabetic foot ulcers: A randomized controlled study. *Diabetes and Metabolic Syndrome*. 2021 Jan 23;15(1):365-371.
43. Vuerstaek JD, Vainas T, Wuite J, Nelemans P, Neumann MH, Veraart JC. State-of-the-art treatment of chronic leg ulcers: A randomized controlled trial comparing vacuum-assisted closure (V.A.C.) with modern wound dressings. *J Vasc Surg* 2006 November 1;44(5):1029-38.
44. Dini V, Miteva M, Romanelli P, Bertone MS, Romanelli M. Immunohistochemical evaluation of venous leg ulcers before and after negative pressure therapy. [Oral Abst 31.4]. Proceedings of the 2010 SAWC/WHs (April 17-20, 2010 Orlando, FL) , S4-S5. 4-17-2010. Ref Type: Abstract
45. Egemen O, Ozkaya O, Ozturk MB, Aksan T, Orman C, Akan M. Effective use of negative pressure wound therapy provides quick wound-bed preparation and complete graft take in the management of chronic venous ulcers. *International Wound Journal*. 2012 Apr;9(2):199-205.

Note: As with any case study, the results and outcomes should not be interpreted as a guarantee or warranty of similar results. Individual results may vary depending on the patient's circumstances and condition.

Note: Specific indications, contraindications, warnings, precautions and safety information exist for these products and therapies. Please consult a physician and product instructions for use prior to application. This material is intended for healthcare professionals.

Note: Disposable components of the Solventum™ V.A.C.® Therapy System, including the foam dressing (i.e., Solventum™ V.A.C.® Granufoam™ Dressing, Solventum™ V.A.C.® Granufoam™ Silver Dressing, or Solventum™ V.A.C.® White Foam Dressing), tubing and drape are packaged sterile and are manufactured without natural rubber latex. V.A.C.® Therapy Unit canisters are packaged fluid path sterile and are manufactured without natural rubber latex. All disposable components of the V.A.C.® Therapy System are for single use only. To help ensure safe and effective use, the V.A.C.® Granufoam, V.A.C.® Granufoam and V.A.C. Whitefoam Dressings are to be used only with V.A.C.® Therapy Units.



Solventum Advanced Wound Care
12930 IH10 W
San Antonio, TX 78249
USA

Phone 800-275-4524
Web Solventum.com

© Solventum 2026. Solventum, the S logo, V.A.C.®, and other trademarks are trademarks of Solventum or its affiliates. 3M and the 3M logo are trademarks of 3M. Other trademarks are the property of their respective owners.

70-2011-8233-7 PRA-PM-US-01523 (12/21)